1-3 of 3
Susan Obrien, MD
Close
Sort by
Journal Articles

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Paolo Strati, MD, Philip A Thompson, MBBS, Michael Keating, MBBS, Christina Hinojosa, Diana Rodriguez, Xuemei Wang, MS, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, William G. Wierda, MD PhD, Hagop M. Kantarjian, MD, Susan Obrien, MD BA, Alessandra Ferrajoli, MD
Journal: Blood
Blood (2016) 128 (22): 4389.
https://doi.org/10.1182/blood.V128.22.4389.4389
Published: 2016
Journal Articles

Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA)

Elias Jabbour, MD, Hagop M Kantarjian, MD, Wei Qiao, Paolo Strati, MD, Navira F Khan, Jorge E. Cortes, MD, Daniela Hoehn, MD, PhD, Jianhua Hu, Susan Obrien, MD, Jeffrey Bryan, Hillary Prescott, Courtney D. DiNardo, MD, Naval Daver, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2013) 122 (21): 2801.
https://doi.org/10.1182/blood.V122.21.2801.2801
Published: 2013
Journal Articles

High Prevalence of FLT3 - ITD Mutations in Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Central Nervous System (CNS) Relapse.

Fabio P S Santos, MD, Hagop Kantarjian, MD, Tapan Kadia, MD, Carol Bivins, RN, Susan Obrien, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Sherry Pierce, RN, Elias Jabbour, MD
Journal: Blood
Blood (2009) 114 (22): 1020.
https://doi.org/10.1182/blood.V114.22.1020.1020
Published: 2009